Table 2

Binding affinities of peptide agonists and nonpeptide antagonists in the wild-type human NK1 receptor and in mutant forms with substitutions in TM-V

hNK1 wild-type[T201A] (V:09)[T201I] (V:09)[T201H] (V:09)[T201H, I204H] (V:09, V:12)
KiKiFmut2-aKiFmutKiFmutKiFmut
nm(n) nm(n) nm(n) nm (n)
Substance P0.11  ± 0.04  (12)0.19  ± 0.03  (12)1.70.14  ± 0.03  (3)1.30.23  ± 0.05  (4)2.10.28  ± 0.02  (13)2.5
SPOMe6.3  ± 1.4  (7)3.4  ± 0.2  (2)0.51.5  ± 0.1  (3)9.0  ± 1.2  (3)1.41.1  ± 0.3  (5)0.2
Ele21  ± 7  (9)8.3  ± 4.7  (3)0.49.3  ± 2.0  (3)0.444  ± 3  (3)2.15.4  ± 1.0  (5)0.3
Neurokinin A14  ± 3  (9)6.8  ± 2.9  (3)0.54.6  ± 0.4  (3)0.323  ± 6  (3)1.63.9  ± 0.9  (5)0.3
CP96,3450.31  ± 0.05  (6)0.40  ± 0.04  (9)1.30.79  ± 0.16  (6)2.514  ± 3  (3)45 260  ± 60  (5)850
CP99,9940.28  ± 0.05  (9)0.49  ± 0.11  (3)1.80.36  ± 0.04  (3)1.33.2  ± 0.2  (3)11 21  ± 4  (4) 75
RP67,58019  ± 4  (7)17  ± 3  (4)0.926  ± 2  (3)1.4120  ± 10  (3)6.3370  ± 70  (3) 20
RPR100,89319  ± 3  (9)13  ± 3  (3)0.710  ± 1  (3)0.5130  ± 10  (3)6.82000  ± 680  (8)110
CAM40923.5  ± 0.8  (9)150  ± 40  (5)43120  ± 10  (3)34 11  ± 1  (3)3.133  ± 7  (4)9.4
CGP49,8230.69  ± 0.13  (8)0.69  ± 0.31  (3)1.00.49  ± 0.07  (4)0.71.5  ± 0.5  (4)2.211  ± 1  (4) 16
LY303,8700.38  ± 0.08  (7)26  ± 11  (4)684.6  ± 0.8  (3)12 3.9  ± 1.1  (4)10 3.8  ± 0.9  (4) 10
FK8881.1  ± 0.1  (7)3.0  ± 1.4  (4)2.71.1  ± 0.3  (4)1.01.5  ± 0.3  (3)1.41.0  ± 0.4  (4)0.9
SR140,3330.44  ± 0.10  (7)0.40  ± 0.10  (5)0.90.33  ± 0.08  (3)0.80.93  ± 0.17  (3)2.14.2  ± 1.6  (4)9.5

Receptors were expressed transiently in COS-7 cells, and competition binding experiments were performed as described in the text using125I-BH-labeled substance P. B max values for the various constructs in fmol/105 cells were hNK1 wild-type, 15 ± 5; [T201A], 130 ± 22; [T201I], 30 ± 9; [T201H], 20 ± 8; and [T201H; I204H], 6.0 ± 1.1.

    • 2-a Fmut is calculated as K i (mutant receptor)/K i (wild-type hNK1 receptor). This corresponds to fold decrease in affinity. Values are mean ± standard error.